Associate Editors-in-Chief

Nathan A. Berger, MD

Departments of Medicine, Biochemistry, Oncology, Genetics & Genome Sciences, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

Dr. Berger is the Hanna-Payne Professor of Experimental Medicine and Director of the Center for Science, Health and Society at Case Western Reserve University School of Medicine. He is Professor of Medicine, Biochemistry, Oncology and Genetics and CWRU Distinguished University Professor.

Dr. Berger attended Temple University, Hahnemann Medical College in Philadelphia, Pennsylvania, served his internship in Medicine at Michael Reese Medical Center, Chicago, Illinois and his residency in Medicine at Barnes Hospital, Washington University, St. Louis, Missouri. From 1968 to 1971 he served as a Lieutenant Commander in the United States Public Health Service and was a Research Associate at the NIH, NICHD Gerontology Research Center, Laboratory of Molecular Biology, Baltimore, Maryland. He completed a fellowship in Hematology and Oncology at Washington University School of Medicine, St. Louis, Missouri and joined the faculty there before moving to Case Western Reserve University School of Medicine in Cleveland, Ohio as Professor of Medicine and Biochemistry and Director of the Hematology/Oncology Division. He became the founding Director of the Case Western Reserve University/Ireland Cancer Center which was awarded NCI Cancer Center status in 1987 and subsequently was designated an NCI Comprehensive Cancer Center. He was Dean of Case Western Reserve University School of Medicine from 1995 to 2002. Since 2002, he has served as Director of the CWRU Center for Science, Health and Society.

Dr. Berger is an active researcher whose early research focused on laboratory and translational aspects of poly (ADP-ribose) polymerase, DNA repair, stress proteins, and developmental therapeutics. His current research focuses on Transdisciplinary Studies in Energy Balance and Cancer and critical aspects of the relations between Aging, Obesity, Energy Balance and Cancer. He is co-director of the NIH funded Specialized Program on Research Excellence in Gastrointestinal Malignancies and on The Barrett’s Esophagus Research Network where he coordinates their pilot projects and career development programs. His laboratory is investigating the mechanisms by by which obesity accelerates and exercise controls cancer progression as well as development of strategies to disrupt these processes.

Dr. Berger’s practice of oncology is located in the Seidman Cancer Center of University Hospitals Case Medical Center and the Case Comprehensive Cancer Center. He has served on many NIH Study Sections and is currently a member of the Basic Mechanism of Cancer Therapy Study Section and also reviews for the NCI Outstanding Investigator Awards. Dr. Berger has over 200 publications and is Editor-In-Chief for the Springer Nature Book Series on Energy Balance and Cancer.

Dr. Berger is an elected member of the American Society of Clinical Investigation and the American Association of Physicians. He was recognized by Case Western Reserve University for his outstanding contributions by award of the 2007 Frank & Dorothy Hovorka Prize, the highest honor conferred by CWRU, for Exceptional Achievements in Teaching, Research and Scholarly Service. In 2010, he was recognized as CWRU SOM Honorary Medical Alumnus of The Year and in 2011, he was awarded a CWRU Distinguished University Professorship.

Editorial Board Member
Terms of Appointment: Jul 2018 – Jun 2020

Associate Editor-in-Chief 
Terms of Appointment: Sep 2019 – Aug 2024

Ja Hyeon Ku, MD, PhD

Associate Professor, Department of Urology, Seoul National University College of Medicine, South Korea

Dr. Ku graduated from Soonchunhyang University School of Medicine (Seoul, South Korea) in 1995. He was trained as a Urology Residency at Soonchunhyang University Hospital from 1996 to 2000, and finally acquired the urology board in 2000. He further completed Urology Fellowship at Seoul National University Hospital between 2003 and 2005. He obtained his PhD degree in Department of Urology at Seoul National University College of Medicine in 2005.

Dr. Ku has been the faculty member and professor in the Department of Urology, Seoul National University College of Medicine since 2007. He also worked as a visiting postdoctoral fellow at Scott Department of Urology, Baylor College of Medicine under Dr. Seth P. Lerner from 2011 to 2012 (Texas, U.S). His clinical and research interests and are primarily focused on urologic oncology, particularly urothelial carcinoma of upper urinary tract and urinary bladder. His area of clinical activities also includes other major urological cancer, including prostate cancer and kidney cancer.

Recently, he has established the translational research laboratory to develop novel biomarkers and therapeutic targets for advanced stage of urothelial carcinoma. Dr. Ku has published more than 150 scientific articles as well as authored textbooks and book chapter in the field of urological oncology. He has been active member of Korean Urological Association and board member of Korean Urological Oncology Society. He also has been serving as an Editorial Board for the Investigative and Clinical Urology, World Research Journal of Surgical Oncology, World Journal of Clinical Oncology, and Journal of Chinese Clinical Medicine.

Editorial Board Member
Terms of Appointment: Nov 2016 – Dec 2018; Jan 2019 – Dec 2020

Associate Editor-in-Chief 
Terms of Appointment: Sep 2019 –Aug 2024

Ling Lu, MD, PhD

Dr. Ling Lu is Division of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Prof. Ling Lu is a surgeon at Division of Liver Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. He is involved in researches concerning liver surgery and transplantation immunology. In the past 15 years, Prof. Lu focuses on the immunology of liver transplantation, especially on the clinical application of regulatory T cells for transplant patients. In the past 5 years, some of these studies have been translated into the clinic for the patients after living donor liver transplantation surgery.

He has peer reviewed many publications for main scientific journals, such as Plos one, Lancet Global Health, Journal of Cellular and Molecular Medicine, and Grant reviews of National Science Foundation of China (NSFC).

Franco M. Muggia, MD

Professor of Medicine, New York University School of Medicine, New York, NY, USA

Dr. Muggia was a senior investigator at the National Cancer Institute from 1969 to 1972, and also Associate Director for the Cancer Therapy Evaluation Program at NCI from 1975 to 1979, during which time he was responsible for the clinical development of cisplatin. He subsequently headed Medical Oncology at New York University (1979-1986; 1996-2009) and the University of Southern California Comprehensive Cancer Center (1986-1996), while also serving as Associate Director for Clinical Investigations at these institutions, and Director of the NYU Kaplan Cancer Center (1997-9). He has led the combined fellowship training program in Hematology/Oncology at New York University Cancer Institute (2006-2010). Other positions and honors include the following: Principal Investigator of a Bristol Myers Squibb Foundation Award to the University of Southern California; Chairman of the Medical Oncology Committee of the Gynecology Oncology Group; Chairman and Medical Director of the Chemotherapy Foundation; member of the executive committee of the Scientific Advisory Board of the American Italian Foundation for Cancer Research, and of the Lynne Cohen Foundation for Ovarian Cancer Research. Also he has co-led international symposia: on Platinum Coordination Compounds in Cancer (2003), and on Hereditary Breast and Ovarian Cancers (2009, 2011). He has authored numerous scientific articles, books, and book chapters. His present interests include: development of anticancer drugs, intraperitoneal therapy for gynecologic and gastrointestinal cancers, and early identification and prevention of cancers in women at high-risk.

Associate Editor-in-Chief 
Terms of Appointment: May 2019 – Apr 2024

Jia Wei, MD, PhD

The Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China

Dr. Jia Wei is now working as a medical oncologist and Associated Professor in the Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University. Dr. Wei is the vice director of cancer center and the Clinical Cancer Institute of Nanjing University. She is also doctoral supervisor of Nanjing University. She received more than one-year training in personalized medicine based on molecular biology under the supervision of Dr. Rafael Rosell from 2007. She is the inaugural STO-CSCO International Fellow and received trainings at Harvard’s Brigham & Women’s Hospital, Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute, Mayo Clinic and the National Cancer Institute. Dr. Wei has experiences of translational researches in gastric cancer. She has authored or co-authored 64 scientific articles in peer-reviewed journals, as well as several book chapters and presentations.

Tung-Sung Tseng, DrPH, MS, CHES/MCHES

Associate Professor, Behavioral and Community Health Sciences, LSUHSC School of Public Health, New Orleans, LA, USA

Dr. Tung-Sung Tseng, is Associate Professor in Behavioral and Community Health Sciences at School of Public Health, Louisiana State University Health Sciences Center in New Orleans. Dr. Tseng is a Certified Health Education Specialist (CHES) / Master Certified Health Education Specialist (MCHES) and co-chairs the Ethics Committee of the Society for Public Health Education (SOPHE). He serve as editor, associate editor and editor board member for several professional journals. He is an active member of the Tobacco Control Initiative (TCI), Design and Analysis Core, LSU’s Improving Clinical Outcomes Network, Health Care Services Division- Innovation Resource Center (HCSD-IRC) and Stanley S. Scott Cancer Center. His primary research interests include tobacco control, childhood obesity, gene-environment interaction, community-based participatory research (CBPR), risk behavioral patterns, health promotion interventions and evaluations, health disparities, and cancer prevention among ethnic minorities and underserved populations. As PI or co-Investigator on several university- and NIH-funded grants, he develop effective intervention approaches and measures of risk behaviors, social determent of health, and other psychosocial factors relevant to the cancer/obesity, and by establishing strong ties with genetic and behaviors intervention as documented in the professional publications.

Editorial Board Member
Terms of Appointment: Nov 2016 – Dec 2018; Jan 2019 – Dec 2020

Associate Editor-in-Chief 
Terms of Appointment: Sep 2019 – Aug 2024